IO Biotech

IO Biotech LT Debt/Equity

Long-Term Debt to Equity Ratio of IO Biotech (IOBT) as of Oct 19, 2026.

LT Debt/Equity

0.00

Last updated:

Long-Term Debt to Equity Ratio of IO Biotech is 2024 0.00 . Long-Term Debt to Equity Ratio of IO Biotech was 2023 0.00 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IO Biotech Stock analysis

What does IO Biotech do? IO Biotech Inc, based in Copenhagen, Denmark, operates in the Health Care sector, specializing in Biotechnology. The company develops immune modulating cancer therapies using its T-win technology platform, focusing on disrupting tumor-induced immunosuppression. Its lead product candidate, IO102-IO103, targets immunosuppressive proteins like IDO and PD-L1. Founded as a spin-off from the National Cancer Center Immune Therapy at Herlev University Hospital, IO Biotech has 57 employees and is listed on the stock exchange since November 5, 2021. IO Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IO Biotech stock

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio IO Biotech since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's IO Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — IO Biotech

All Key Metrics — IO Biotech